Extended Data Fig. 6: Adverse events in sex, age, ECOG matched COVID-19-vaccinated and unvaccinated immune checkpoint therapy treated cancer patients, related to Fig. 4. | Nature Cancer

Extended Data Fig. 6: Adverse events in sex, age, ECOG matched COVID-19-vaccinated and unvaccinated immune checkpoint therapy treated cancer patients, related to Fig. 4.

From: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy

Extended Data Fig. 6: Adverse events in sex, age, ECOG matched COVID-19-vaccinated and unvaccinated immune checkpoint therapy treated cancer patients, related to Fig. 4.

(a) Schema indicating the propensity score based matching procedure. (b) Bar graphs indicating the proportional difference of sex and ECOG before and after propensity score matching (upper panel, n = 26 unvaccinated and n = 26 matched vaccinated patients). Xy plot indicating the empirical cumulative distribution function (eCDF) of vaccinated (n = 26) and unvaccinated (n = 26) patients before and after matching. (c) Bar graphs indicating frequencies and error bars the 95% confidence interval of all (upper panel) or grade ≥3 (lower panel) adverse events in matched vaccinated (n = 26) and unvaccinated (n = 26) patients. This is proportional data therefore the confidence interval is asymmetric and the center is the bar.

Source data

Back to article page